Cell therapy markets to balloon worldwide, near $3 billion by 2000.MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--April 18, 1995--Worldwide cell therapy revenues will mushroom mushroom, type of basidium fungus characterized by spore-bearing gills on the underside of the umbrella- or cone-shaped cap. The name toadstool is popularly reserved for inedible or poisonous mushrooms, but this classification has no scientific basis. , growing by more than 200 times from a relatively insignificant $13 million in 1994 to over $2.7 billion by the year 2000 at a compound annual rate well above 100 percent, projects a new study just released by Frost & Sullivan. Sales of immunomodulatory therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. will rise from 29 percent of the total cell therapy market in 1994 to 54 percent by 1998 before dipping to 47 percent by the year 2000 while tissue repair cell therapies correspondingly dip in share, from 71 percent in 1994 to 53 percent in 2000, though growing enormously in absolute terms (Alg.) such as are known, or which do not contain the unknown quantity. See also: Absolute , forecasts the report, WORLD CELL THERAPY MARKETS: HARNESSING THE POWER OF THE CELL. Extremely rapid growth will begin in the 1995-96 period as new tissue repair therapies penetrate large markets, particularly for wound healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by and cartilage cartilage (kär`təlĭj), flexible semiopaque connective tissue without blood vessels or nerve cells. It forms part of the skeletal system in humans and in other vertebrates, and is also known as gristle. repair, and as the first directly therapeutic immunomodulatory therapies provide new alternatives for cancer treatment. The latter will command higher prices than current immunomodulatories, which play an adjunctive role. Other immunomodulatory therapies are under development as direct therapies against cancers, viral diseases viral diseases Diseases caused by viruses. Long-term immunity usually follows viral childhood diseases (see chickenpox). The common cold recurs into adulthood because many different viruses cause its symptoms, and immunity against one does not protect against others. , autoimmune autoimmune /au·to·im·mune/ (-i-mun´) directed against the body's own tissue; see under disease and response. au·to·im·mune adj. and inflammatory disorders, diabetes and neurological disorders This is a list of major and frequently observed neurological disorders (e.g. Alzheimer's disease), symptoms (e.g.back pain), signs (e.g. aphasia) and syndromes (e.g. Aicardi syndrome). . Competition from other emerging treatment modalities treatment modality Medtalk The method used to treat a Pt for a particular condition like gene therapy late in the decade will slow revenue growth somewhat. Application of cell therapies in conjunction with other, more established treatment modalities is being investigated with increasing intensity. At least one firm is incorporating a cell therapy component into a multidisciplinary mul·ti·dis·ci·pli·nar·y adj. Of, relating to, or making use of several disciplines at once: a multidisciplinary approach to teaching. wound healing treatment strategy. Other companies are investigating concurrent application of cell therapy and chemotherapy. Some cell therapies, particularly many targeting cancers, are providing a location where chemotherapeutics can be applied to cells externally to the patient in greater concentrations than could be applied directly. Certain firms are investigating application of multiple cell therapies. The first tissue repair cell therapies reached the market in 1988 as a treatment for severe burns. Other wound healing therapies were introduced more recently. In 1993, the first immunomodulatory therapy, hematopoietic stem cell Hematopoietic stem cell A cell that can develop into any type of specialized blood cell. Mentioned in: Umbilical Cord Blood Banking therapy, reached the European market as a cancer chemotherapy adjunct adjunct (aj´ungkt), n a drug or other substance that serves a supplemental purpose in therapy. adjunct . Nearly 30 firms are directly developing new cell therapies, including eleven in tissue repair therapies and 19 immunomodulatories. Cell therapy involves administration to humans of living cells processed in such a way as to change their characteristics other than by introduction of foreign genetic material. Frost & Sullivan is an international high-technology research firm. All Frost & Sullivan reports are based on extensive interviews with marketing and technical experts from selected companies in each market segment. Primary research is validated by thorough analysis of available secondary research. Frost & Sullivan is the leading publisher worldwide of high- technology research reports. -0- Report: 5033-52 Publication Date: April 1995 Price: $2895
Total Cell Therapy Market:
Revenue Forecasts (World),
1990-2000
Revenue
Revenues Growth
Year ($ mil) (%)
1990 5.9 --
1991 6.0 2.0
1992 7.8 29.0
1993 6.4 (17.7)
1994 13.3 107.8
1995 54.7 311.0
1996 166.4 204.2
1997 455.4 173.7
1998 965.4 112.0
1999 1,790.4 85.5
2000 2,736.8 52.9
CAGR 137.6
Source: Frost & Sullivan CONTACT: Frost & Sullivan Amy Arnell (Mountain View), 415/961-9000 415/961-5042 (fax) Kristina Menzefricke (London), 44 171 730 3438 44 171 730 3343 (fax) Nadge Keryhuel (Paris), 33 1 4742 9127 33 1 4742 9129 (fax) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion